Real-World Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in US Patients with Stage I–III Resected NSCLC Without Known EGFR Mutations: The RESECT Study
Most patients received surgery alone, though the proportion receiving systemic treatment increased with disease stage. Modest 5-year, real-world relapse-free survival rates indicate a need for more effective neoadjuvant or adjuvant treatments in this setting.
Authors
- Jhanelle E. Gray (ORCID: https://orcid.org/0000-0003-1304-7062)
- I. Diaz Perez
- Ling Cai (ORCID: https://orcid.org/0000-0002-8592-5269)
- Claire Fielden
- R. Salomonsen
- Nefeli Georgoulia
- G. Barrie Wetherill
- Alice Wang (ORCID: https://orcid.org/0000-0003-4468-9367)
- Yang Xiao (ORCID: https://orcid.org/0009-0006-5606-3969)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Moffitt Cancer Center (US)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1007/s40801-025-00487-w
- Citations
- 1
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- AstraZeneca